Stocks · News reference
Oral GLP-1 weight-loss pills are driving a health-tech boom, but research on their safe use is struggling to keep pace.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
FDA approval supported by data from BRAVE-AA-PEDS, the first and largest Phase 3 study specifically designed to evaluate pediatric patients with severe alopecia areata (AA)Treatment with Olumiant resulted in
Nektar Therapeutics wins $90 million jury verdict against Eli Lilly in lawsuit over their rezpegaldesleukin licensing agreement.
Viking Therapeutics released positive maintenance dosing data for its GLP-1 drug candidate VK2735, causing the stock to surge 35%. The company is positioning itself as a potential competitor in the $100 billion weight loss drug market dominated by Eli Lilly and Novo Nordisk. Viking's dual GLP-1/GIP agonist could be the first oral formulation of its kind, with both injectable and oral versions available, offering advantages over current competitors.
Novo Nordisk eyes M&A to counter patent cliff risks, and partners with Nanexa for long-acting injectables.
Viking Therapeutics stock jumps 40% after VK2735 shows sustained weight loss with less frequent dosing.